ACTA2 and neoplasm: Our accompanying paper on KPCM experimental models (KrasG12D/+; Trp53R172H/+; Pdx-1-Cre; Muc16-/-) shows that knockout of Muc16 in tumor cells substantially decreases α-SMA (Acta2) levels in CAFs.